-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|October 21, 2022

Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.

Episodes in this series

EP. 1 Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

EP. 1 Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

EP. 2 Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)

EP. 2 Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)

EP. 3 EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

EP. 3 EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

EP. 4 SOGUG-AUREA Study Overview

EP. 4 SOGUG-AUREA Study Overview

EP. 5 SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

EP. 5 SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

EP. 6 Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

EP. 6 Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

EP. 7 Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

EP. 7 Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Yonatan S. Resnick, PharmD | Image: NECS

Considerations for Use of Tebentafusp, a BiTE Approved for Rare, High-Risk Uveal Melanoma

ByYonatan S. Resnick, PharmD

August 4th 2026

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

August 3rd 2026

Brittany Craiglow, MD in part 1 of an AJMC Q&A

The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 3rd 2026

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health